Dalteparin sodium
As of the edition of 20 October 2026, Dalteparin sodium is an oligosaccharide: marketed, first approved in 1987 (FR); acts on SERPINC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1995
- Kind
- Oligosaccharide
- Brand name
- Fragmin
- First approved
- 4 December 1987 (FR)
- Approvals on record
- 24 in 4 regions
- Holder of the most recent approval
- Pfizer
- Registered trials
- 60, 14 stopped early
- Disease areas
- Heart and blood vessels; Cancer; Lungs and airways; Digestive system; Blood and lymph; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Dalteparin sodium.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SERPINC1 | Antithrombin-III | P01008 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 17 | 12 | 1 | 3 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 12 | 7 | 0 | 5 |
| Phase 3 | 16 | 11 | 0 | 3 |
| Phase 4 | 14 | 7 | 4 | 3 |
| All trials | 60 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 1988 to now |